

27 May 2009

For immediate release

BGMA launches new website

The BGMA has today launched a new website to showcase the contribution the industry makes to the UK and NHS.

The new website includes:

- briefings about the key issues that face the industry such as MHRA performance and the EU Commission's pharma inquiry
- an e-forum for members to discuss public policy matters
- new Q&A and myth busting sections
- an image library to showcase the industry

Kim Innes, the Chairman of the BGMA, stated:

My aim in my term as Chairman is to give the BGMA a greater voice for its work in helping to make healthcare stay affordable. We have a great story to tell in the generics industry, so the launch of the new website is just one example of how the BGMA is raising its profile and arguing the case for cost-effective, high quality generic medicines that save the NHS £7 billion a year – money that can be used to stimulate innovation and afford access to new, expensive treatments.

With two new members (Consilient Health & Arrow Generics) joining the BGMA in recent weeks, more than ever we're an effective Association at creating value in healthcare; and the message that the new website spreads is that generic medicines are at the heart of sustainability in the NHS.

Note for Editors:

The website address is: www.britishgenerics.co.uk

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. 64% of all medicines dispensed by the NHS are generics yet they cost only 29% of the NHS drugs bill, a saving of around £7.5bn in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level. The average cost to the NHS of a generic medicine is £4.62, whilst the average cost of a branded medicine is £20. Competition from generics also stimulates the research based pharmaceutical industry to develop new medicines.

Our 19 members account for around 85% of the UK generics market by volume. Their work keeps medicines affordable for the Department of Health which allows further investment in other healthcare

priorities, and promotes innovation in the development of new medicines. We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.

Further information: Warwick Smith: 020 7457 2065 or 07974 565 424 or James Nason: 020 7457 2862 or 07917 085 945